Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Revenue (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Revenue for 10 consecutive years, with $207.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Revenue rose 25.89% to $207.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $673.0 million, a 20.18% increase, with the full-year FY2025 number at $673.0 million, up 20.18% from a year prior.
  • Revenue was $207.3 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $159.9 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $207.3 million in Q4 2025 to a low of $79.9 million in Q1 2022.
  • A 5-year average of $119.1 million and a median of $105.8 million in 2022 define the central range for Revenue.
  • Peak YoY movement for Revenue: surged 173.75% in 2021, then decreased 19.58% in 2022.
  • Ultragenyx Pharmaceutical's Revenue stood at $83.4 million in 2021, then increased by 23.93% to $103.3 million in 2022, then rose by 23.02% to $127.1 million in 2023, then increased by 29.5% to $164.6 million in 2024, then rose by 25.89% to $207.3 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Revenue are $207.3 million (Q4 2025), $159.9 million (Q3 2025), and $166.5 million (Q2 2025).